Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis
- PMID: 15851026
- DOI: 10.1016/j.cell.2005.02.031
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis
Abstract
Tuberous sclerosis (TSC) is a tumor syndrome caused by mutation in TSC1 or TSC2 genes. TSC tumorigenesis is not always accompanied by loss of heterozygosity (LOH). Recently, extracellular signal-regulated kinase (Erk) has been found activated in TSC lesions lacking TSC1 or TSC2 LOH. Here, we show that Erk may play a critical role in TSC progression through posttranslational inactivation of TSC2. Erk-dependent phosphorylation leads to TSC1-TSC2 dissociation and markedly impairs TSC2 ability to inhibit mTOR signaling, cell proliferation, and oncogenic transformation. Importantly, expression of an Erk nonphosphorylatable TSC2 mutant in TSC2+/- tumor cells where Erk is constitutively activated blocks tumorigenecity in vivo, while wild-type TSC2 is ineffective. Our findings position the Ras/MAPK pathway upstream of the TSC complex and suggest that Erk may modulate mTOR signaling and contribute to disease progression through phosphorylation and inactivation of TSC2.
Similar articles
-
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.Cancer Res. 2007 Aug 1;67(15):7106-12. doi: 10.1158/0008-5472.CAN-06-4798. Cancer Res. 2007. PMID: 17671177
-
Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.J Cell Biol. 2002 Oct 28;159(2):217-24. doi: 10.1083/jcb.jcb.200206108. Epub 2002 Oct 28. J Cell Biol. 2002. PMID: 12403809 Free PMC article.
-
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. doi: 10.1073/pnas.0405659101. Epub 2004 Sep 1. Proc Natl Acad Sci U S A. 2004. PMID: 15342917 Free PMC article.
-
The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review.
-
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6. doi: 10.4161/cbt.2.5.446. Cancer Biol Ther. 2003. PMID: 14614311 Review.
Cited by
-
Active mechanistic target of rapamycin plays an ancillary rather than essential role in zebrafish CNS axon regeneration.Front Cell Neurosci. 2015 Jul 7;9:251. doi: 10.3389/fncel.2015.00251. eCollection 2015. Front Cell Neurosci. 2015. PMID: 26217179 Free PMC article.
-
FAM83B mediates EGFR- and RAS-driven oncogenic transformation.J Clin Invest. 2012 Sep;122(9):3197-210. doi: 10.1172/JCI60517. Epub 2012 Aug 13. J Clin Invest. 2012. PMID: 22886302 Free PMC article.
-
(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.Front Oncol. 2016 Jun 15;6:135. doi: 10.3389/fonc.2016.00135. eCollection 2016. Front Oncol. 2016. PMID: 27379200 Free PMC article.
-
Aberrant REDD1-mTORC1 responses to insulin in skeletal muscle from Type 2 diabetics.Am J Physiol Regul Integr Comp Physiol. 2015 Oct 15;309(8):R855-63. doi: 10.1152/ajpregu.00285.2015. Epub 2015 Aug 12. Am J Physiol Regul Integr Comp Physiol. 2015. PMID: 26269521 Free PMC article.
-
Key factors in mTOR regulation.Cell Mol Life Sci. 2010 Jan;67(2):239-53. doi: 10.1007/s00018-009-0163-7. Epub 2009 Oct 13. Cell Mol Life Sci. 2010. PMID: 19823764 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous